Printer Friendly
The Free Library
14,588,558 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CHAD Therapeutics Reports Fiscal 2007 First Quarter Financial Results and Provides Update on Evaluation of Strategic Opportunities.


CHATSWORTH Chatsworth, estate, Derbyshire, central England, near Chesterfield. It is the seat of the dukes of Devonshire. Begun in 1552, the present Classical-style Chatsworth House was rebuilt in 1686. , Calif. -- CHAD Therapeutics therapeutics

Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry.
, Inc. (AMEX AMEX

See: American Stock Exchange
:CTU CTU Colorado Technical University
CTU Czech Technical University in Prague
CTU Counter Terrorist Unit
CTU Clinical Trials Unit
CTU Catholic Theological Union
CTU Chicago Teachers Union
CTU Computer Training Unit
CTU Control Unit
) today reported financial results for the first quarter of fiscal 2007, and provided an update on the Company's evaluation of strategic alternatives to maximize shareholder value.

First Quarter Fiscal 2007 Results

For the three months ended June June: see month.  30, 2006, revenue declined to $5,476,000 from $5,895,000 for the quarter ended June 30, 2005. The net loss for the first quarter of fiscal 2007 was $116,000, or $0.01 per share, compared to a net loss of $42,000, or $0.00 per share, for the first quarter of fiscal 2006.

Revenue from sales of oxygen conservers and therapeutic devices declined 7% for the first quarter of fiscal 2007 compared to the same quarter of fiscal 2006, reflecting a 17% decline in sales to domestic customers and a 42% increase in international sales. The decline in domestic sales was primarily due to pricing pressure as unit sales unit sales

Sales measured in terms of physical units rather than dollars. Unit sales data are often used by financial analysts when evaluating the health of a company.
 declined by 5%. Sales of CHAD's proprietary TOTAL O(2)(R) home oxygen filling system decreased 17% for the first quarter of fiscal 2007 compared to the same quarter of fiscal 2006. Selling, general and administrative expenses for this year's first quarter included $42,000 of legal and other expenses incurred in evaluating various strategic opportunities.

President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  Earl Yager Ya´ger

n. 1. (Mil.) In the German army, one belonging to a body of light infantry armed with rifles, resembling the chasseur of the French army.
 said, "As we have discussed previously, effective January January: see month.  1, 2006, Medicare Medicare, national health insurance program in the United States for persons aged 65 and over and the disabled. It was established in 1965 with passage of the Social Security Amendments and is now run by the Centers for Medicare and Medicaid Services.  reimbursement Reimbursement

Payment made to someone for out-of-pocket expenses has incurred.
 procedures were modified to provide that patients automatically acquire ownership of equipment they are using to provide oxygen after 36 months. By intensifying in·ten·si·fy  
v. in·ten·si·fied, in·ten·si·fy·ing, in·ten·si·fies

v.tr.
1. To make intense or more intense:
 pressure on homecare British Gas HomeCare is the name for British Gas Services which operates in the United Kingdom, which was originally set up to provide maintenance for central heating and other gas appliances.  providers to reduce operating and equipment costs, we continue to believe that this policy ultimately will stimulate demand for CHAD's TOTAL O(2) home oxygen filling system, which is a cost-effective cost-effective,
n the minimal expenditure of dollars, time, and other elements necessary to achieve the health care result deemed necessary and appropriate.
 solution to the changing economics of the home oxygen market. However, our customers have remained in a `wait and see' mode until important questions are answered regarding equipment repair and the provision of oxygen to patients after the transfer of title. We have taken appropriate steps to adjust our operating model Operating Model is a term that is used in many contexts. In essence an operating model describes how an organization operates across both business and technology domains. The Operating Model describes what is important for the organization.  and inventory posture posture /pos·ture/ (pos´choor) the attitude of the body.pos´tural

pos·ture
n.
1. A position of the body or of body parts.

2.
 in light of these developments.

"An additional potentially positive development is that the Centers for Medicare & Medicaid Medicaid, national health insurance program in the United States for low-income persons; established in 1965 with passage of the Social Security Amendments and now run by the Centers for Medicare and Medicaid Services.  Services ("CMS (1) See content management system and color management system.

(2) (Conversational Monitor System) Software that provides interactive communications for IBM's VM operating system.
"), which administers the Medicare reimbursement program, recently proposed a modification in the monthly payments for oxygen starting on January 1, 2007. This proposal would reduce the current monthly payment for stationary Stationary can mean:
  • Fixed in position, or mode: immobile.
  • Unchanging in condition or character.
  • In statistics and probability: a stationary process.
  • In mathematics: a stationary point.
  • In mathematics: a stationary set.
 oxygen but provide an additional payment for transfilling systems such as CHAD's TOTAL O(2) system. A final determination on this proposal is expected later this year."

Yager added, "The international marketplace also continues to provide encouraging opportunities for CHAD. International conserver con·serve  
v. con·served, con·serv·ing, con·serves

v.tr.
1.
a. To protect from loss or harm; preserve:
 sales are increasing, and by the end of this year we expect to see significant sales from one or two additional international markets."

The CEO continued, "We also are continuing our efforts to expand our product offerings, and are pleased by our progress in the development of proprietary diagnostic and therapeutic products for the sleep disorder Sleep disorder
Any condition that interferes with sleep. At least 84 have been identified, according to the American Sleep Disorders Association.

Mentioned in: Insomnia, Night Terrors
 market. Evaluations of this technology at a university sleep clinic have resulted in certain modifications to the initial products we are developing. This work is now substantially complete. While a number of important steps remain, we are currently planning to introduce commercial products for the sleep disorder market by the spring of 2007." (Please see the discussion below under "Safe Harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 Statements" regarding risk factors which might delay introduction of these products or affect their prospects for commercial success.)

Working capital was approximately $9.7 million at June 30, 2006, including cash and cash equivalents of $1,704,000 versus $935,000 at March 31, 2006. The Company has no debt.

Update on Evaluation of Strategic Opportunities

As previously reported, CHAD has been considering various strategic alternatives for the Company, and has engaged an investment banking firm to assist the Board in this process. "The Board has concluded that current opportunities do not offer our shareholders sufficient value. While we will continue to evaluate appropriate strategic opportunities as they may arise, we intend to focus on improving our operating results and expanding our product offerings, and to explore distribution and marketing partnerships for certain of our products," Yager said.

About CHAD Therapeutics

CHAD Therapeutics, Inc. is in the business of developing, producing and marketing respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary pulmonary /pul·mo·nary/ (pool´mo-nar?e)
1. pertaining to the lungs.

2. pertaining to the pulmonary artery.


pul·mo·nar·y
adj.
Of, relating to, or affecting the lungs.
 diseases. For more information, visit www.CHADtherapeutics.com.

Safe Harbor Statements under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995.

The foregoing statements regarding prospects for future earnings and revenues, future sales trends and the introduction of products under development are forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 that involve certain risks and uncertainties. A number of important factors could cause actual results to differ materially from those contemplated by such forward-looking statements. These include the potential loss of one of our major customers upon whom we depend for a material portion of our business, increased competition and continuing downward pressure on prices for certain of our products, the potential introduction of new products with perceived competitive advantages over the Company's products, changes or proposed changes in health care reimbursement which affect homecare providers, the terms of any distribution agreement which may be negotiated with respect to our TOTAL O(2) system or our sleep products, and CHAD's ability to anticipate and respond to technological and economic changes in the home oxygen market. The projected timing for the introduction of new products may be delayed as a result of unforeseen difficulties encountered in the design, manufacture and quality testing for such products. The Company has limited design and manufacturing resources and it relies to a significant extent upon independent contractors A person who contracts to do work for another person according to his or her own processes and methods; the contractor is not subject to another's control except for what is specified in a mutually binding agreement for a specific job.  for the development of products for the sleep disorder market. As a result, the Company may have more difficulty ensuring adherence adherence /ad·her·ence/ (ad-her´ens) the act or condition of sticking to something.

immune adherence
 to projected timetables for the introduction of such products. Moreover, the success of the Company's products and products under development will depend on their efficacy, reliability and the health care community's perception of the products' capabilities and benefits, the degree of acceptance the products achieve among homecare providers and, with respect to products under development, obtaining timely regulatory approval. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Company's annual and quarterly reports filed with the Securities and Exchange Commission under the caption "Risk Factors."
CHAD THERAPEUTICS, INC.
                  CONDENSED STATEMENTS OF OPERATIONS
                             (Unaudited)

                                             Three Months Ended
                                                  June 30,
                                      --------------------------------
                                            2006            2005
                                      ---------------- ---------------

Net sales                             $     5,476,000  $    5,895,000
Cost of sales                               3,662,000       3,794,000
                                       ---------------  --------------

  Gross profit                              1,814,000       2,101,000

 Selling, general and administrative        1,702,000       1,844,000
 Research and development                     335,000         332,000
                                       ---------------  --------------

  Total costs and expenses                  2,037,000       2,176,000
                                       ---------------  --------------

Operating income (loss)                      (223,000)        (75,000)

Other income, net                              23,000           6,000
                                       ---------------  --------------

Earnings (loss) before income taxes          (200,000)        (69,000)

Income tax (benefit)                         ( 84,000)        (27,000)
                                       ---------------  --------------

  Net earnings (loss)                 $      (116,000) $      (42,000)
                                       ---------------  --------------

Earnings (loss) per share:
  Basic                               $         (0.01) $         0.00
  Diluted                             $         (0.01) $         0.00
                                       ---------------  --------------

Weighted shares outstanding:
  Basic                                    10,169,000      10,134,000
  Diluted                                  10,169,000      10,134,000


                       CHAD THERAPEUTICS, INC.
                       CONDENSED BALANCE SHEETS
                             (Unaudited)

                                                  June 30,
Assets                                      2006            2005
                                      ---------------- ---------------

Current assets:
 Cash                                 $     1,704,000  $      471,000
 Accounts receivable, net                   3,184,000       3,301,000
 Income taxes refundable                      290,000              --
 Inventories, net                           6,257,000       8,147,000
 Prepaid expenses and other assets            159,000         145,000
 Deferred income taxes                        662,000         488,000
                                       ---------------  --------------

  Total current assets                     12,256,000      12,552,000
                                       ---------------  --------------

Property, plant and equipment, net            901,000       1,166,000
Intangible assets, net                      1,038,000         837,000
Deferred income taxes                         613,000         568,000
Other assets                                   55,000          67,000
                                       ---------------  --------------

  Total Assets                        $    14,863,000  $   15,190,000
                                       ---------------  --------------


Liabilities and Shareholders' Equity

Current liabilities:
 Accounts payable                     $     1,009,000  $      775,000
 Accrued expenses                           1,523,000       1,421,000
 Income taxes payable                              --          12,000
                                       ---------------  --------------

  Total current liabilities                 2,532,000       2,208,000

Other long-term liabilities                     2,000              --
                                       ---------------  --------------

  Total liabilities                         2,534,000       2,208,000
                                       ---------------  --------------

Shareholders' equity:
 Common shares, $.01 par value,
  authorized 40,000,000 shares,
  10,158,000 and 10,134,000 issued
  and outstanding                          13,463,000      13,369,000
 Accumulated deficit                       (1,134,000)       (387,000)
                                       ---------------  --------------

  Shareholders' equity                     12,329,000      12,982,000
                                       ---------------  --------------

  Total Liabilities and Shareholders'
   Equity                             $    14,863,000  $   15,190,000
                                       ===============  ==============
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:CHAD Therapeutics Reports Fiscal 2007 First Quarter Financial Results and Provides Update on Evaluation of Strategic Opportunities.
Publication:Business Wire
Geographic Code:1USA
Date:Aug 11, 2006
Words:1404
Previous Article:Philips and BG Medicine Form Alliance for Molecular Medicine Research and Development; Partners to Embark upon Joint Development of Molecular Imaging...
Next Article:Dyadic Reports 2006 Second Quarter Financial Results.
Topics:



Related Articles
Chad running out of gas as others ply oxygen market. (Chad Therapeutics Inc.)
BIZWATCH : MARKETS.(BUSINESS)
CHAD hitches star to smaller portable oxygen tank. (Up Front).(CHAD Therapeutics Inc)
CHAD managers beat out dissidents in proxy battle. (Corporate Focus).(CHAD Therapeutics Inc.)
Device credited for CHAD boost.(Chad Therapeutics Inc.)
CHAD Therapeutics Reports Fiscal 2006 Second Quarter and First Half Financial Results; Announces Engagement of Investment Bank to Assist Management...
CHAD Therapeutics Reports Fourth Quarter and Fiscal 2006 Financial Results and Provides Update on Evaluation of Strategic Opportunities.
CHAD Therapeutics Reports Fiscal 2007 Second Quarter and First Half Financial Results.
Briefly.(Public Companies)
CHAD Therapeutics Reports Fiscal 2007 Third Quarter and Nine Months Financial Results.(Financial report)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles